Abstract:Key Points Question To what extent do global polygenic risk scores (PRS), molecular pathway-specific PRS, complement component (C4) gene expression, MHC loci, sex, and ancestry jointly contribute to risk for schizophrenia-spectrum disorders (SZ)? Findings Global polygenic risk for schizophrenia, sex, and their interaction most robustly predict risk in a classification and regression tree model, with highest risk groups having 50/50 chance of SZ. Meaning Psychometric risk indicators, such as prodromal symptom assessments, may be enhanced by the examination of genetic risk metrics. Preliminary results suggest that of genetic risk metrics, global polygenic information has the most potential to significantly aide in the prediction of SZ. Abstract Importance Schizophrenia (SZ) has a complex, heterogeneous symptom presentation with limited established associations between biological markers and illness onset. Many (gene) molecular pathways (MPs) are enriched for SZ signal, but it is still unclear how these MPs, global PRS, major histocompatibility complex (MHC) complement component (C4) gene expression, and MHC loci might jointly contribute to SZ and its clinical presentation. It is also unclear whether sex or ancestry interacts with these metrics to increase risk in certain individuals. Objective To examine multiple genetic metrics, sex, and their interactions as possible predictors of SZ risk. Genetic information could aid in the clinical prediction of risk, but it is still unclear which genetic metrics are most promising, and how sex interacts with genetic risk metrics. Design, Setting, and Participants To examine molecular risk in a proof-of-concept study, we used the Wellcome Trust case-control cohort and classified cases as a function of 1) polygenic risk score (PRS) for both whole genome and for 345 implicated molecular pathways, 2) predicted C4 expression, 3) SZ-relevant MHC loci, 4) sex, and 5) ancestry. Main Outcomes and Measures PRSs, C4 expression, SZ-relevant MHC loci, sex, and ancestry as joint risk factors for SZ. Results Recursive partitioning yielded 15 molecular risk classes and retained as significant psychosis classifiers only sex, genome-wide SZ polygenic risk, and one MP PRS. Sex was the most robust classifier in a stepwise regression, and there was a significant interaction of sex with SZ PRS on case status, suggesting males have a lower polygenic risk threshold. By down-sampling case proportion to 1% and 1.4% population base rates in males and females, respectively, high-risk subtypes defined by this model had roughly a 52% odds of developing SZ (individuals with SZ PRS elevated by 2.6 SDs; incidence = 51.8%). Conclusions and Relevance This proof-of-concept suggests that global SZ PRS, sex, and their interaction are robust predictors of risk and that males have a lower PRS threshold for onset. Implications for the integration of these metrics with psychometrically-identified risk are discussed.

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Polygenic liability for antipsychotic dosage and polypharmacy - a real-world registry and biobank study

Predicting Treatment Response in Schizophrenia With Magnetic Resonance Imaging and Polygenic Risk Score

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

Incremental predictive value of genetic risk and functional brain connectivity in determining antipsychotic response in schizophrenia

Schizophrenia polygenic risk scores, clinical variables and genetic pathways as predictors of phenotypic traits of bipolar I disorder

Enhancing Suicide Risk Prediction With Polygenic Scores in Psychiatric Emergency Settings: Prospective Study

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Applications of Polygenic Risk Scores in Psychiatric Genetics.

Different Responses to Risperidone Treatment in Schizophrenia: a Multicenter Genome-Wide Association and Whole Exome Sequencing Joint Study

Polygenic risk scores: from research tools to clinical instruments

Proof of concept: Molecular prediction of schizophrenia risk

Optimization of Multi-Ancestry Polygenic Risk Score Disease Prediction Models

Identifying and characterizing disease subpopulations that most benefit from polygenic risk scores

Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes

Can artificial neural networks supplant the polygene risk score for risk prediction of complex disorders given very large sample sizes?

The Clinical Usefulness of a Glaucoma Polygenic Risk Score in 4 Population-Based European Ancestry Cohorts

Genetic liability in individuals at ultra-high risk of psychosis: A comparison study of 9 psychiatric traits

Psychiatric polygenic risk scores: Experience, hope for utility, and concerns among child and adolescent psychiatrists

A polygenic risk score model for psoriasis based on the protein interactions of psoriasis susceptibility loci